Human Chronic Lymphoid Leukemia Bone Marrow Plasma (Relapsed/Refractory)

Description

Human Chronic Lymphoid Leukemia Bone Marrow Plasma (Relapsed/Refractory) is isolated from the bone marrow of patients diagnosed with relapsed or refractory chronic lymphocytic leukemia (CLL). These samples represent the tumor microenvironment in advanced stages of disease and include plasma components and circulating tumor-derived factors. CLL is a malignancy of mature B lymphocytes and often exhibits heterogeneity in treatment response and disease progression. The collected bone marrow plasma is cryopreserved immediately post-processing to preserve cytokines, exosomes, and soluble immune mediators. Relapsed/refractory CLL plasma frequently contains elevated levels of sCD23, CCL3, and soluble PD-L1, which can be quantified via ELISA or multiplex assays. They provide valuable insight into immune evasion, resistance mechanisms, and stromal interactions in the CLL bone marrow niche. Repeated freeze-thaw cycles are discouraged to prevent degradation of labile biomolecules and vesicle rupture. Each lot undergoes rigorous screening and isolation procedures, and is rigorously tested to ensure it is free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.